Investigation announced for Investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) over possible Violations of Securities Laws

An investigation was announced concerning potential securities laws violations by Allarity Therapeutics, Inc in connection with certain financial statements.

Investors who purchased shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Allarity Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Boston, MA based Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.

On July 22, 2024, before market hours Allarity Therapeutics, Inc. filed a current report on Form 8-K with the Securities and Exchange Commission ("SEC"), in which the Company disclosed that: "Allarity Therapeutics, Inc. (the 'Company') received a 'Wells Notice' from the Staff of the U.S. Securities and Exchange Commission (the 'SEC') relating to the Company's previously disclosed SEC investigation."
Allarity Therapeutics, Inc. also revealed that "[t]he Wells Notice relates to the Company's disclosures regarding meetings with the United States Food and Drug Administration (the 'FDA') regarding the Company's NDA [New Drug Application] for Dovitinib or Dovitinib-DRP," and that "Allarity also understands that three of its former officers received Wells Notices from the SEC relating to the same conduct." Further, "[t]he Wells Notice informed the Company that the SEC Staff has made a preliminary determination to recommend that the SEC file an enforcement action against the Company that would allege certain violations of the federal securities laws."

Shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR) declined to $0.138 per share on August 07, 2024.

Those who purchased shares of Allarity Therapeutics, Inc. (NASDAQ: ALLR) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.